Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 10;9(3):395–410. doi: 10.1002/cpdd.762

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Novartis Institutes of BioMedical Research Inc. Clinical Pharmacology in Drug Development published by Wiley Periodicals, Inc. on behalf of American College of Clinical Pharmacology

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.

PMC Copyright notice

Pharmacokinetic‐pharmacodynamic relationship. Scatter plots of (A) FGF19 observed maximum plasma concentration following drug administration (C_max) vs tropifexor C_max and (B) FGF area under the plasma concentration‐time curve from time 0 to 24 h (AUC_0‐24h) vs tropifexor AUC_0‐24h following single ascending doses of tropifexor in fasted subjects. Scatter plots of (C) FGF C_max vs tropifexor C_max and (D) FGF AUC_0‐24h vs tropifexor AUC_0‐24h following multiple ascending doses of tropifexor in lean healthy subjects.